Published in Gut on January 01, 2004
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev (2006) 7.72
Inflammation, atrophy, and gastric cancer. J Clin Invest (2007) 4.29
Proton pump inhibitors and gastric neoplasia. Gut (2006) 1.90
Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol (2007) 1.57
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
The role of microRNAs in gastrointestinal cancers. J Gastroenterol (2009) 1.17
Gastrin - active participant or bystander in gastric carcinogenesis? Nat Rev Cancer (2006) 1.05
Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol (2010) 0.98
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag (2007) 0.94
Barrett esophagus: an update. Nat Rev Gastroenterol Hepatol (2010) 0.92
Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol (2007) 0.91
Helicobacter pylori eradication for gastric cancer prevention. J Gastroenterol (2007) 0.89
Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer (2014) 0.87
Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut (2004) 0.85
Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer (2015) 0.84
The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut (2005) 0.82
The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterol J (2013) 0.81
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol (2016) 0.79
H pylori infection and reflux oesophagitis. Gut (2004) 0.79
Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol (2014) 0.79
Factors associated with the development of reflux esophagitis after Helicobacter pylori eradication. Dig Dis Sci (2006) 0.79
Gastric epithelial cell modality and proton pump inhibitor. J Clin Biochem Nutr (2008) 0.78
Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus. World J Gastroenterol (2014) 0.78
Helicobacter pylori infection is the major risk factor for gastric inflammation in the cardia. Dig Dis Sci (2006) 0.77
HelicoBase: a Helicobacter genomic resource and analysis platform. BMC Genomics (2014) 0.77
Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol (2017) 0.75
Do we need to eradicate Helicobacter pylori in patients with GORD? United European Gastroenterol J (2013) 0.75
Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol (2015) 0.75
Heartburn issues burnt out? J Gastroenterol (2005) 0.75
Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol (2017) 0.75
Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 21.37
Helicobacter pylori infection and the development of gastric cancer. N Engl J Med (2001) 17.13
Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res (1992) 12.77
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med (1989) 5.78
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology (1999) 4.41
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology (2000) 2.99
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (2001) 2.88
Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut (1995) 2.20
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer (1985) 1.89
Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology (2001) 1.87
Histopathological classification of nonantral gastric endocrine growths in man. Digestion (1988) 1.85
Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch (1998) 1.79
Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology (1997) 1.67
TECHNICAL NOTE: A SILVER METHOD FOR PARAFFIN SECTIONS OF NEURAL TISSUE. J Neuropathol Exp Neurol (1965) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology (1997) 1.56
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology (2001) 1.50
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med (2001) 1.30
Silver stains in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol (1980) 1.27
High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther (2000) 1.27
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther (2002) 1.23
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol (2000) 1.21
Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut (2001) 1.20
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter (2000) 1.12
Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther (2000) 1.07
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut (1997) 1.07
Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther (2001) 1.05
Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion (2001) 1.04
The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther (1999) 1.03
Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol (1998) 0.99
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1998) 0.99
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut (2000) 0.99
Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol (1996) 0.97
The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther (1999) 0.89
Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther (1999) 0.87
Gastric corpus atrophy following eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2001) 0.86
Acid suppression and gastric atrophy: sifting fact from fiction. Gut (1998) 0.85
Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med (1997) 0.84
Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Pathol Res Pract (1998) 0.83
Inability to noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with Helicobacter pylori eradication. J Clin Gastroenterol (2001) 0.82
Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol (2000) 0.81
Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. Z Gastroenterol (1998) 0.80
Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol (2001) 0.78
Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection. Dig Dis Sci (2001) 0.77
Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother (1983) 8.82
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet (2000) 5.31
Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest (1980) 5.11
Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med (1982) 5.07
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology (1999) 4.41
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut (2004) 3.85
Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet (1978) 3.69
Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet (1976) 3.61
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51
A new technique for continuous sphincter pressure measurement. Gastroenterology (1976) 3.44
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04
Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 2.91
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (2001) 2.88
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg (2007) 2.66
Pathogenesis of reflux esophagitis. Gastroenterology (1981) 2.58
Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology (1995) 2.53
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol (1998) 2.44
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett (1996) 2.42
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Toxicological studies on omeprazole. Scand J Gastroenterol Suppl (1985) 2.19
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology (1995) 2.12
Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2009) 2.11
Behavior and gastroesophageal reflux in the premature neonate. J Pediatr Gastroenterol Nutr (2000) 2.07
Hydatidiform mole in England and Wales 1973-83. Lancet (1986) 2.05
[Guideline "Dyspepsia"]. Ned Tijdschr Geneeskd (2005) 2.02
Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1990) 1.95
Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology (1994) 1.94
Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. Am J Physiol (1988) 1.89
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol (1996) 1.86
Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology (2000) 1.86
Histopathological classification of nonantral gastric endocrine growths in man. Digestion (1988) 1.85
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol (2000) 1.81
Manometric disorders in patients with suspected sphincter of Oddi dysfunction. Gastroenterology (1985) 1.75
Origin of spiral organisms in human gastric antrum. Lancet (1988) 1.72
Upper esophageal sphincter function during deglutition. Gastroenterology (1988) 1.71
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut (1996) 1.71
The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut (2001) 1.70
Utilization of paraffin-embedded material for electron microscopy. Study of an A2-cell type microadenoma of the endocrine pancreas. Lab Invest (1970) 1.70
Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology (1997) 1.70
Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol (1997) 1.69
Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology (1986) 1.66
Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther (2000) 1.65
Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut (1985) 1.64
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut (2001) 1.62
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology (1997) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther (2004) 1.61
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol (1979) 1.59
Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. Aliment Pharmacol Ther (2010) 1.59
Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet (1995) 1.59
Motor activity of the gastric antrum, pylorus, and duodenum under fasted conditions and after a liquid meal. Gastroenterology (1988) 1.57
Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion (1986) 1.56
Control of belching by the lower oesophageal sphincter. Gut (1990) 1.54
Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol (1986) 1.53
Upper esophageal sphincter function during belching. Gastroenterology (1986) 1.50
A comparison of transnasal and transoral endoscopy with small-diameter endoscopes in unsedated patients. Gastrointest Endosc (1999) 1.50
Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology (1988) 1.50
Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut (1999) 1.49
Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. Gastroenterology (1986) 1.49
Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust (1992) 1.48
Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol (2001) 1.47
Efficient utilization of echocardiography for the assessment of left ventricular systolic function. Am Heart J (2000) 1.46
A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol (1986) 1.46
Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut (1988) 1.44
Human duodenal phase III migrating motor complex activity is predominantly antegrade, as revealed by high-resolution manometry and colour pressure plots. Neurogastroenterol Motil (2002) 1.44
Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol (1984) 1.44
Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol (1997) 1.44
The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother (1984) 1.43
Interdigestive phasic contractions of the human lower esophageal sphincter. Gastroenterology (1983) 1.43
Follow-up of Helicobacter pylori positive gastritis and argyrophil cells pattern during the natural course of gastric ulcer. Helicobacter (1998) 1.41
Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid. Antimicrob Agents Chemother (1983) 1.40
Effect of cisapride on secondary peristalsis in patients with gastroesophageal reflux disease. Am J Gastroenterol (1999) 1.40
The importance of the pylorus as a regulator of solid and liquid emptying from the stomach. J Gastroenterol Hepatol (1996) 1.40
Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer (1983) 1.40
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology (1999) 1.40